trending Market Intelligence /marketintelligence/en/news-insights/trending/DxrslKutR7qgZEc4Kf8RBQ2 content esgSubNav
In This List

CTD Holdings medicine secures rare pediatric disease designation from US FDA

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


CTD Holdings medicine secures rare pediatric disease designation from US FDA

CTD Holdings, Inc. secured a rare pediatric disease designation for Trappsol Cyclo from the U.S. Food and Drug Administration.

The medication is used in the treatment of a rare and fatal genetic disease, Niemann-Pick type C, that affects the brain, lung, liver, spleen and other organs.

The rare pediatric disease designation is granted to drugs that have the potential to treat orphan diseases affecting fewer than 200,000 patients in the U.S. and with more than 50% of those affected age 18 years or younger.

The medication is undergoing a phase 1 trial in the U.S. and a phase 1/2 trial in Europe and Israel. The company recently filed an application to conduct a clinical trial in Italy.

The treatment earlier secured orphan drug designations in the U.S. and the European Union.